ATyr Pharma, Return On Assets Over Time
| ATYR Stock | 3.53 0.09 2.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ATyr Pharma, Performance and ATyr Pharma, Correlation. ATyr |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ATyr Pharma,. If investors know ATyr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ATyr Pharma, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.009 | Return On Assets (0.33) | Return On Equity (0.62) |
The market value of aTyr Pharma, is measured differently than its book value, which is the value of ATyr that is recorded on the company's balance sheet. Investors also form their own opinion of ATyr Pharma,'s value that differs from its market value or its book value, called intrinsic value, which is ATyr Pharma,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ATyr Pharma,'s market value can be influenced by many factors that don't directly affect ATyr Pharma,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ATyr Pharma,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if ATyr Pharma, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ATyr Pharma,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Assets Analysis
Compare aTyr Pharma, and related stocks such as Ardelyx, Regeneron Pharmaceuticals, and Acumen Pharmaceuticals Return On Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARDX | (0.2583) | (0.2583) | (0.2583) | (0.153) | (0.0283) | (0.2533) | (0.5273) | (0.4075) | (0.498) | (0.3655) | (0.4679) | (1.055) | (0.3536) | (0.222) | (0.23) |
| REGN | (0.1299) | (0.1675) | 0.3606 | 0.1438 | 0.0899 | 0.1134 | 0.1284 | 0.1367 | 0.2083 | 0.1429 | 0.2047 | 0.3175 | 0.1485 | 0.1195 | 0.13 |
| ABOS | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (1.0738) | (0.1648) | (0.7888) | (0.2059) | (0.1689) | (0.18) |
| BNTX | (0.2286) | (0.2286) | (0.2286) | (0.2286) | (0.2286) | (0.2286) | (0.2286) | (0.2286) | (0.0735) | (0.2246) | 0.0066 | 0.6502 | 0.4053 | 0.0404 | 0.0658 |
| RDCM | 0.0133 | (0.0892) | (0.3152) | (0.0723) | 0.0357 | (0.0458) | 0.0351 | 0.0316 | (0.027) | (0.0709) | (0.0426) | (0.0574) | (0.0223) | 0.0345 | 0.0363 |
| TARS | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.5521) | (0.0801) | (0.1559) | (0.0773) | (0.2725) | (0.5119) | (0.54) |
| IRDM | (0.0076) | 0.0289 | 0.0337 | 0.0271 | 0.0258 | 0.0022 | 0.0317 | 0.0618 | (0.0033) | (0.0447) | (0.0167) | (0.0029) | 0.003 | 0.0058 | 0.0076 |
| SYRE | (0.3235) | (0.3235) | (0.3235) | (0.3235) | (0.3235) | (0.3235) | (0.3235) | (0.4857) | (0.5705) | (0.9407) | (0.5005) | (0.5986) | (1.1781) | (0.991) | (1.04) |
aTyr Pharma, and related stocks such as Ardelyx, Regeneron Pharmaceuticals, and Acumen Pharmaceuticals Return On Assets description
A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.My Equities
My Current Equities and Potential Positions
| aTyr Pharma, | ATYR |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
null 3.53
Additional Tools for ATyr Stock Analysis
When running ATyr Pharma,'s price analysis, check to measure ATyr Pharma,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ATyr Pharma, is operating at the current time. Most of ATyr Pharma,'s value examination focuses on studying past and present price action to predict the probability of ATyr Pharma,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ATyr Pharma,'s price. Additionally, you may evaluate how the addition of ATyr Pharma, to your portfolios can decrease your overall portfolio volatility.